Invuity Company Profile (NASDAQ:IVTY)

Invuity trades on the NASDAQ under the ticker symbol "IVTY."

Invuity, Inc. (NASDAQ:IVTY) issued its earnings results on Wednesday, April, 26th. The company reported ($0.64) EPS for the quarter, missing the Zacks' consensus estimate of ($0.61) by $0.03. The business earned $9.02 million during the quarter, compared to analyst estimates of $8.71 million. Invuity had a negative net margin of 118.92% and a negative return on equity of 129.81%. View Invuity's Earnings History.

5 equities research analysts have issued twelve-month price objectives for Invuity's shares. Their predictions range from $10.00 to $25.00. On average, they expect Invuity's stock price to reach $16.50 in the next twelve months. View Analyst Ratings for Invuity.

Here are some recent quotes from research analysts about Invuity stock:

• 1. According to Zacks Investment Research, "Invuity, Inc. is a medical technology company. Its products include Eikon Illuminated Retractor System, Saber Yankauer, Saber Frazier, Eika Illuminated Retractor System, Breiten Illuminated Retractor System, Eipex Illuminated Retractor System, Eivector Illuminated Retractor System and Waveguide XT System. The Company sells its devices through its direct sales representatives and original equipment manufacturers of surgical systems. Invuity, Inc. is based in San Francisco, California. " (6/27/2017)
• 2. Stifel Nicolaus analysts commented, "Following Invuity's early January top-line pre-announcement giving a potential $9.1M-$9.3M revenue range, the company's full 4Q16 release and call provided both more positive details on the quarter and critical revenue measures, all of which suggests the business has stabilized after slower than expected 3Q16 results. At $9.4M, 4Q16 sales were a touch ahead of the company's preliminary range. Encouragingly, revenue per account at $12,100 (+10% Y/Y, 5% Q/Q) -- a critical measure for assessing the company's "go-deep" strategy -- appears stable. Equally impressive, the company continued to expand its active hospital account base which now stands at 745 (+41% Y/Y). Management again reaffirmed 2017 top-line guidance of $42M-$44M, which, in our view, could prove conservative given 4Q16 stable revenue/account, new accounts adds, and "modest" contribution from the mid-year 2017 expected full launch of PhotonBlade. We continue to believe Invuity's highly differentiated, and expanding, portfolio of procedure enhancing technologies will continue to demonstrate meaningful growth potential across a broad array of medical specialties. At current valuation levels, 1.6x 2018 EV/R (peer group: ~3.0x), Invuity would appear undervalued, given the company's significant top-line growth outlook. We rate Invuity shares Buy with a now higher $9 (from $8) target price." (2/15/2017)

Some companies that are related to Invuity include Veracyte (VCYT), Idera Pharmaceuticals (IDRA), DURECT Corporation (DRRX), Pharming Group (PHGUF), Voyager Therapeutics (VYGR), Zynerba Pharmaceuticals (ZYNE), ObsEva SA (OBSV), Ardelyx (ARDX), Pieris Pharmaceuticals (PIRS), Corvus Pharmaceuticals (CRVS), Organovo Holdings (ONVO), Clearside Biomedical (CLSD), Catalyst Pharmaceuticals (CPRX), Stemline Therapeutics (STML), Tabula Rasa Healthcare (TRHC), Fortress Biotech (FBIO), Chimerix (CMRX) and Osiris Therapeutics (OSIR).

(IVTY) raised $48 million in an initial public offering on the week of June 15th 2015. The company issued 4,000,000 shares at $12.00 per share. Piper Jaffray, Leerink Partners and Stifel acted as the underwriters for the IPO and William Blair was co-manager.

Invuity's stock is owned by a number of of institutional and retail investors. Top institutional investors include InterWest Venture Management Co (6.36%) and Well Done LLC (2.16%). Company insiders that own Invuity stock include Alex Vayser, Eric W Roberts, Gregory T Lucier, James E Flynn, James H Mackaness, Philip M Sawyer, Reza Zadno and Robert Gerberich. View Institutional Ownership Trends for Invuity.

Shares of Invuity can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Invuity stock can currently be purchased for approximately $8.20.